Month: April 2020

MALVERN, Pa., April 08, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced preliminary first quarter 2020 revenue and provided a business update, including the actions it is taking in response to COVID-19.“During these uncertain times, our first priority is the health and safety of our employees, patients, customers and communities. Depression is a debilitating condition that millions of patients suffer from worldwide, and for those undergoing or in need of treatment, we believe that TMS treatment is a medical necessity. We continue to support our customers and the patients they serve during these challenging times,” said...

BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will continue to be reimbursed for those patients in England who suffer from cluster headache and respond to our therapy.“We are pleased to have NHS England maintain their ITP program to fund and support bringing our gammaCore therapy to patients suffering from cluster headache. gammaCore remains the only device approved by the National Institute for Health and Care Excellence...

MIDLAND, Texas, April 08, 2020 (GLOBE NEWSWIRE) — Steven West, Chairman of the Board of Directors (the “Board”) of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback” or the “Company”), is pleased to announce that effective April 3, 2020, the Company increased the size of Diamondback’s Board of Directors to eight members, adding Stephanie K. Mains and Vincent K. Brooks as independent directors.Stephanie Mains has over 30 years of experience across diverse industrial segments, including aviation, energy and transportation. Most recently, she served as President and CEO of ABB Electrification Products Industrial Solutions, a $2.7 billion leading provider of advanced technologies to protect, control and optimize assets within electrical infrastructures for a number of industrial, commercial and residential...

LIVERMORE, Calif., April 08, 2020 (GLOBE NEWSWIRE) — McGrath RentCorp (NASDAQ: MGRC) (the “Company”), a diversified business-to-business rental company, today announced plans to release financial results for its first quarter ending March 31, 2020, after the close of regular market trading on Wednesday, April 29, 2020.McGrath RentCorp will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that afternoon to discuss the results.  There will also be a live Q&A session.  The conference call may be accessed by dialing 1-844-707-0666 (international callers dial 1-703-639-1220), or by listening to the simultaneous webcast on https://investors.mgrc.com/.  A replay will be available for 7 days following the call by dialing 1-855-859-2056 (international callers dial 1-404-537-3406).  The passcode for conference...

CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15th at 9:20 a.m. EDT.A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. Replays of the webcasts will be archived for 90 days following the conferences.About Genocea Biosciences, Inc.Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types.  Our unique ATLAS™ platform comprehensively...

SOUTH SAN FRANCISCO, Calif., April 08, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today announced preliminary unaudited revenue for the three months ended March 31, 2020 and withdrew its previously issued full year 2020 revenue guidance.First Quarter RevenuePreliminary revenue for the three months ended March 31, 2020 is expected to be $38.3 million, an increase of 47% compared with $26.0 million in the first quarter of 2019. In the quarter, the Company provided approximately 15,000 patient results, increasing 50% year-over-year. The preliminary information presented in this press release is based on CareDx’s current expectations...

Dorman facilities and global supply chain continue to meet current customer demand levelsProactive steps taken to manage costs, enhance liquidity and bolster balance sheetGiven uncertainty of COVID-19 pandemic, Dorman withdraws fiscal 2020 guidanceDorman announces it will report first quarter 2020 financial results on April 27, 20202020 Annual Meeting of Shareholders to be held virtuallyCOLMAR, Pa., April 08, 2020 (GLOBE NEWSWIRE) — Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ:DORM), a leading supplier in the automotive aftermarket industry, today provided an update on its business operations in light of the ongoing Coronavirus (COVID-19) pandemic.“First and foremost, the health and safety of our employees, customers, and suppliers remain our utmost priority,” said Kevin Olsen, President and Chief Executive Officer...

SOUTH SAN FRANCISCO, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, at 10:40 AM EST.Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.About CytokineticsCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class...

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF) announced today that it plans to release its first quarter results for the period ended March 31, 2020 after market close on Thursday, May 7, 2020. Altus Group executives Robert Courteau, Chief Executive Officer, and Angelo Bartolini, Chief Financial Officer, will host a conference call and webcast at 5:00 p.m. (ET) the same day to review the financial results and discuss corporate developments.Q1 2020 Results Conference Call & WebcastAbout Altus Group LimitedAltus Group Limited is a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Our businesses, Altus Analytics and Altus Expert Services, reflect decades of experience, a range of expertise, and...

Pratteln, Switzerland, April 8, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that the number of its shares recorded in the commercial register has been increased from 11,164,563 shares by 1,150,000 shares to 12,314,563 shares.On April 8, 2020, 1,150,000 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares under the equity-linked financing provided by IRIS announced earlier today.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age....